This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

FDA Post-Marketing Safety Decisions

Donald F. Klein, MD

Published: August 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The U.S. Food and Drug Administration (FDA) black box warning that antidepressants increase the risk of suicidal thinking and behavior in children was followedby a sharp fall in antidepressant prescriptions. No procedure for estimating the net public health impact exists.1 No suicide occurred in clinical trials of approximately 4400 children, but the term suicidality clearly implies a high degree of lethal risk.’ ‹

Volume: 67

Quick Links: Psychopharmacology

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Free CME: Academic Highlights

Diagnosing and Treating Alzheimer Disease During the Early Stage

Many new therapies for early-stage AD have made their way onto the scene that can delay onset...